Search Results

Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Takara Bio USA, Inc. announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.

Takara Bio USA, Inc. today announced plans to launch two critical solutions for oncology research. These automated single-cell total RNA-seq and DNA-seq library preparation kits will provide high sample and cell throughput, less hands-on time, and the ability to capture more information than other available technologies.

Takara Bio USA, Inc., a pioneering life science reagent and instrument company and wholly owned subsidiary of Takara Bio Inc., is partnering with BioExcel Diagnostics to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases.

Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).

The Biocodex Microbiota Foundation is announcing the 2024 open call for applications for its annual USA research grant.

Coya Therapeutics, Inc. announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.

Matinas BioPharma Holdings, Inc. announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.